The EVARREST® Fibrin Sealant Patch Liver Study

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2014

Conditions
Hemorrhage
Interventions
BIOLOGICAL

EVARREST® Fibrin Sealant Patch

OTHER

Standard of Care (SoC)

Trial Locations (17)

3004

Clinical Investigation Site #3, Melbourne

5011

Clinical Investigation Site #2, Woodville South

10032

Clinical Investigation Site #11, New York

10065

Clinical Investigation Site #14, New York

15213

Clinical Investigation Site #17, Pittsburgh

19107

Clinical Investigation Site #8, Philadelphia

30912

Clinical Investigation Site #10, Augusta

35294

Clinical Investigation Site #13, Birmingham

60611

Clinical Investigation Site #16, Chicago

60637

Clinical Investigation Site #12, Chicago

63110

Clinical Investigation Site #9, St Louis

70121

Clinical Investigation Site #15, New Orleans

93-503

Clinical Investigation Site #1, Auckland

B15 2TH

Clinical Investigation Site #6, Birmingham

CB2 0QQ

Clinical Investigation Site #7, Cambridge

EH16 4SA

Clinical Investigation Site #4, Edinburgh

LS9 7TF

Clinical Investigation Site #5, Leeds

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT01993888 - The EVARREST® Fibrin Sealant Patch Liver Study | Biotech Hunter | Biotech Hunter